AMARIN COMPLETES TWO TRIALS IN HUNTINGTON'S DISEASE

Amarin has completed the treatment phase of both the North American and European Phase III clinical trials of Miraxion for the treatment of Huntington's disease. More than 600 patients were enrolled in the trials, representing the largest clinical program in Huntington's disease ever undertaken. Following data validation and analysis, the company expects to report top-line trial results during the second quarter.

The primary endpoint of the trials is a change in the Total Motor Score 4 component of the Unified Huntington's Disease Rating Scale. In addition, secondary endpoints include cognition, behavioral and Total Functional Capacity outcomes. The patients were randomized to receive either placebo or 2 grams of Miraxion for a period of six months.

Patients in the trials may now switch to an open-label extension period where all patients will receive Miraxion and will continue to be assessed in accordance with the trial protocol.

Motor dysfunction is a prominent and progressively deteriorating feature of Huntington's disease, an ultimately fatal genetic disease causing uncontrolled movements, loss of intellectual faculties, emotional disturbances, psychosis and dementia, according to Amarin. Currently, there are no FDA-approved treatments for Huntington's disease, the company said.

In addition to Huntington's disease, Amarin is testing the effectiveness of Miraxion in treating depressive disorders and Parkinson's disease.